Evidence map›Paper›PMID 32797053›Full record

ArticlePloS one2020

Characteristics of pulmonary multidrug-resistant tuberculosis patients in Tigray Region, Ethiopia: A cross-sectional study.

Letemichael Negash Welekidan, Eystein Skjerve, Tsehaye Asmelash Dejene, Mengistu Welday Gebremichael, Ola Brynildsrud, Angelika Agdestein, Girum Tadesse Tessema, Tone Tønjum, Solomon Abebe Yimer

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 28 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 5 pooled it
0.4field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 5 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Letemichael Negash WelekidanDepartment of Para Clinical Sciences, Norwegian University of Life Sciences, Oslo, Norway.ORCID 0000-0003-0763-0841
Eystein SkjerveDepartment of Production Animal Medicine, Norwegian University of Life Sciences, Oslo, Norway.
Tsehaye Asmelash DejeneDepartment of Medical Microbiology and Immunology, Division of Biomedical Sciences, College of Health Sciences, Mekelle University, Mekelle, Ethiopia.
Mengistu Welday GebremichaelDepartment of Midwifery, College of Health Sciences, Mekelle University, Mekelle, Ethiopia.
Ola BrynildsrudDepartment of Para Clinical Sciences, Norwegian University of Life Sciences, Oslo, Norway.
Angelika AgdesteinSection for Microbiology, Norwegian Veterinary Institute, Oslo, Norway.
Girum Tadesse TessemaSection for Microbiology, Norwegian Veterinary Institute, Oslo, Norway.
Tone TønjumDepartment of Microbiology, Unit for Genome Dynamics, University of Oslo, Oslo, Norway.ORCID 0000-0002-1709-6921
Solomon Abebe YimerDepartment of Bacteriology and Immunology, Norwegian Institute of Public Health, Oslo, Norway.
Mekelle University · ETNorwegian Institute of Public Health · NONorwegian University of Life Sciences · NONorwegian Veterinary Institute · NOOslo University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTuberculosis (TB) is among the top 10 causes of mortality and the first killer among infectious diseases worldwide. One of the factors fuelling the TB epidemic is the global rise of multidrug resistant TB (MDR-TB). The aim of this study was to determine the magnitude and factors associated with MDR-TB in the Tigray Region, Ethiopia.

methodThis study employed a facility-based cross-sectional study design, which was conducted between July 2018 and August 2019. The inclusion criteria for the study participants were GeneXpert-positive who were not under treatment for TB, PTB patients' ≥15 years of age and who provided written informed consent. A total of 300 participants were enrolled in the study, with a structured questionnaire used to collect data on clinical, sociodemographic and behavioral factors. Sputum samples were collected and processed for acid-fast bacilli staining, culture and drug susceptibility testing. Drug susceptibility testing was performed using a line probe assay. Logistic regression was used to analyze associations between outcome and predictor variables.

resultsThe overall proportion of MDR-TB was 16.7% (11.6% and 32.7% for new and previously treated patients, respectively). Of the total MDR-TB isolates, 5.3% were pre-XDR-TB. The proportion of MDR-TB/HIV co-infection was 21.1%. A previous history of TB treatment AOR 3.75; 95% CI (0.7-2.24), cigarette smoking AOR 6.09; CI (1.65-2.50) and patients who had an intermittent fever (AOR = 2.54, 95% CI = 1.21-5.4) were strongly associated with MDR-TB development.

conclusionsThe magnitude of MDR-TB observed among new and previously treated patients is very alarming, which calls for an urgent need for intervention. The high proportion of MDR-TB among newly diagnosed cases indicates ongoing transmission, which suggests the need for enhanced TB control program performance to interrupt transmission. The increased proportion of MDR-TB among previously treated cases indicates a need for better patient management to prevent the evolution of drug resistance. Assessing the TB control program performance gaps and an optimal implementation of the WHO recommended priority actions for the management of drug-resistant TB, is imperative to help reduce the current high MDR-TB burden in the study region.

Indexed as

AdolescentAdultAgedAged, 80 and overAntitubercular AgentsCross-Sectional StudiesEthiopiaFemaleHIV InfectionsHumansIsoniazidMaleMicrobial Sensitivity TestsMiddle AgedMycobacterium tuberculosisRifampinAntitubercular AgentsIsoniazidRifampin

Identifiers

PMID32797053
PMCPMC7428183
OpenAlexW3049570022

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.